Meflocid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meflocid

Meflocid: What is it?

Property Description
Active Ingredient Levofloxacin
Form Tablets, Oral Solution, Intravenous Solution
Pharmacological Class Third-Generation Fluoroquinolone
General Purpose Systemic bacterial clearance
Origin Synthetic (S-enantiomer of Ofloxacin)

Meflocid: Classification and Active Ingredient Identity

Meflocid is a powerful, synthetic, prescription-only product classified as a broad-spectrum antibiotic designed for treating systemic bacterial infections. The active ingredient is Levofloxacin, which is a highly effective antibacterial agent for fighting serious infections. Levofloxacin belongs to the third-generation fluoroquinolone class of antibacterials. This classification indicates a drug with established efficacy against a wide range of both Gram-positive and Gram-negative bacteria, characterized by its dual-target action.

Primary Purpose and Bactericidal Action

The general purpose of Meflocid is to achieve the systemic clearance of susceptible bacterial pathogens responsible for various types of infections in the body. Levofloxacin exerts a bactericidal effect, meaning its core action is to directly kill the targeted bacteria, which distinguishes it from agents that only inhibit growth. This provides a robust solution for situations such as complicated urinary tract infections, where a decisive elimination of the pathogen is necessary. This action is achieved by interfering with the bacteria’s core genetic machinery: Levofloxacin specifically inhibits the vital bacterial enzymes, DNA-gyrase and DNA topoisomerase IV.

Available Forms and Composition

Levofloxacin, the active component, is prepared for systemic use in several standard pharmaceutical forms, including solid tablets, an oral solution, and a solution for intravenous (IV) injection. This preparation versatility allows for administration via both oral and intravenous routes. A key differentiating factor is that Levofloxacin is the stereochemically pure S-enantiomer (or L-isomer) of the older racemic drug, Ofloxacin. This structural refinement focuses the drug on the active molecular configuration, providing enhanced potency and reduced inactive burden compared to the older compound.

What side effects are possible with Meflocid?

Possible Side Effects and Safety Information

The safety profile of Meflocid (Levofloxacin) is formally defined by regulatory authorities based on observed adverse reactions and established safety patterns. Side effects are classified by frequency and grouped by the body system affected, ensuring transparent communication of risk.

Frequency and System-Organ Classifications

Adverse reactions are organized into official frequency categories, as documented in prescribing information.

Classification Examples of Documented Effects
Common (1 in 100 to 1 in 10) Nausea, Diarrhea, Headache, Dizziness, Insomnia, increased liver enzymes
Uncommon (1 in 1,000 to 1 in 100) Vomiting, Abdominal pain, Arthralgia (joint pain), Rash, Anxiety, Somnolence
Rare (1 in 10,000 to 1 in 1,000) Tendinitis, Hypoglycemia (low blood sugar), Convulsion, Prolonged QT interval, Angioedema

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight specific serious risks. These include Tendinitis and Tendon Rupture (which may be delayed or occur quickly), Peripheral Neuropathy (which can manifest as tingling or numbness), Aortic Aneurysm and Aortic Dissection, and Severe Hepatotoxicity. Serious hypersensitivity reactions and effects on the Central Nervous System are also documented.

Safety constraints note that use is generally restricted in Pediatric Patients and individuals with a history of Myasthenia Gravis. Older Adults and patients taking Corticosteroids are designated as populations with an increased documented risk for tendon disorders. Furthermore, certain serious effects, like tendon rupture, have been noted to occur as early as within 48 hours of starting treatment or up to several months after discontinuation.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Meflocid (mefenamic acid) requires immediate attention, particularly with severe symptoms or in specific populations. While lower doses may result in milder effects like epigastric pain, nausea, and vomiting, massive ingestions carry a higher risk for serious toxicity.

Overdose Presentations and Risks

The primary concern with mefenamic acid overdose is a high, dose-related risk of Central Nervous System (CNS) toxicity, which may include confusion, agitation, disorientation, and convulsions (seizures). Ingestions of more than 3.5 grams have been reported to cause seizures. In cases of severe or massive overdose, presentations may progress to include coma, shock, and acute renal failure.

When to Seek Immediate Medical Help

Seek urgent medical attention and expert consultation with a toxicologist immediately if an overdose is suspected. Hospital admission for observation is required for all symptomatic children and in cases of intentional overdose. Any patient presenting with seizures, altered conscious level, signs of shock, or symptoms indicating possible acute renal failure requires emergency medical treatment.

Management of Overdose

Management of mefenamic acid overdose is primarily supportive, focusing on maintaining vital functions (resuscitation and supportive care). Ensuring adequate hydration is a critical component of treatment following large overdoses to mitigate the potential for acute kidney injury. There is no specific antidote.

Therapeutic Uses of Meflocid

Meflocid is applied in contexts marked by increased discomfort or tension. Its therapeutic applications span multiple major systems and are commonly used across conditions presenting with acute episodes.

Management of Acute Respiratory and Systemic Infections

The medication is relevant for treating infections of the lower respiratory tract, notably community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis, as well as acute bacterial sinusitis. This use supports the patient during difficult episodes by easing distress related to fever, difficulty breathing, or the production of purulent sputum, which are all symptoms that interfere with daily functioning.

Treatment of Complicated Urinary and Deep-Seated Conditions

Meflocid is used across conditions presenting with acute episodes in the urinary system, specifically complicated urinary tract infections (cUTIs) and acute infections of the kidney (acute pyelonephritis). This therapeutic action helps address symptom clusters that may become intense, such as severe flank pain and painful urination. It is also relevant in clinical settings, such as chronic bacterial prostatitis, where it is used to manage symptoms related to physical discomfort.

Quick Fact: Relief for Systemic Discomfort
Meflocid contributes to easing the overall symptom load in conditions involving acute fever, localized pain, and functional stress.

Regulatory References

  1. NIH DailyMed drug label overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Meflocid

Regulatory agencies define strict population criteria for the use of Meflocid (Levofloxacin).

Category Official Regulatory Status
Populations for whom use is allowed Adults (ge 18 years of age). Pediatric patients (ge 6 months of age) only for the specific, life-threatening conditions of Inhalational Anthrax (post-exposure) and Plague.
Populations for whom use is contraindicated Patients with known hypersensitivity to Levofloxacin or any other quinolone/fluoroquinolone. Patients with a history of epilepsy or tendon disorders related to previous fluoroquinolone use. Children and growing adolescents (generally <18 years of age) for general indications.
Pregnancy and lactation eligibility Contraindicated in pregnant and breast-feeding women.

Condition-Specific Eligibility Restrictions

Eligibility is conditional for several patient groups:

  • Renal Impairment: Use is restricted and requires a mandatory dosage adjustment for patients with impaired kidney function (Creatinine Clearance <50 mL/min) to avoid drug accumulation.
  • Comorbidity Risk: Use is advised to be avoided in patients with a known history of Myasthenia Gravis or conditions that prolong the QT interval. Caution is required for older adults (ge 60 years), patients taking corticosteroids, or those with a history of organ transplant, as these factors increase the risk of serious tendon disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Prohibited and Pharmacodynamic Interactions

Co-administration of Meflocid (Levofloxacin) with specific antiarrhythmic agents, including Pimozide, Thioridazine, and Dronedarone, is formally contraindicated in regulatory labeling. This restriction is due to the documented risk of additive QT interval prolongation with these agents. Official labeling notes that co-administration with Antidiabetic Agents (e.g., Insulin) carries a risk of dysglycemia, necessitating careful observation. Similarly, co-use with Corticosteroids is associated with a documented increased risk of tendinopathy and tendon rupture.


Absorption and Clearance Constraints

Products containing multivalent cations, such as Antacids, Sucralfate, and supplements with Iron or Zinc salts, must be separated from Meflocid administration. Failure to separate administration by at least 2 hours before or 2 hours after the Meflocid dose results in reduced oral absorption and lower antibiotic bioavailability. Furthermore, the effect of the anticoagulant Warfarin may be enhanced, requiring careful observation of coagulation status. The drug's renal clearance is reduced by co-administration with Probenecid or Cimetidine, a transporter-mediated interaction that increases Levofloxacin exposure.


Population Notes

Regulatory documents note that Geriatric patients (65 years) may have increased susceptibility to both tendinopathy (with Corticosteroids) and QT prolongation risks.

Mechanism of Action

Meflocid (Levofloxacin) is a bactericidal agent whose mechanism centers on the deliberate destruction of the target pathogen's genetic integrity. The mechanism of action is rooted in the drug's ability to simultaneously interfere with two essential bacterial enzymes.

Targeting the Bacterial DNA Regulation Enzymes

This mechanism acts as an inhibitor of Bacterial DNA Gyrase (Topoisomerase II) and Topoisomerase IV, the enzymes essential for managing DNA supercoiling and chromosome separation. By binding to these enzymes when they are attached to the DNA, the drug initiates a bactericidal mechanistic cascade.

The Cascade of Irreversible DNA Damage

Meflocid stabilizes the transient enzyme-DNA complex, preventing the enzymes from completing the necessary step of re-ligating (rejoining) the cut DNA strands. This stabilization results in the rapid accumulation of irreparable double-strand DNA breaks across the bacterial genome, which triggers a catastrophic failure of all genetic processes. The physiological consequence of this is bactericidal action.

Mechanisms of Bacterial Evasion

The drug's action is constrained if bacteria acquire genetic mutations in the target genes (gyrA or parC), which reduces Meflocid's binding affinity, or if they activate efflux pumps, which are proteins that actively pump the drug out of the cell. These evasion strategies diminish the mechanism's ability to drive the irreversible DNA damage.

Dosage and Administration Information

How to use Meflocid

The administration of Meflocid (Levofloxacin) is standardized across multiple forms. The medication is officially approved for both oral administration (tablets and solution) and intravenous (IV) infusion. Due to their bioequivalence, patients can often be switched from IV to oral therapy at the same dose once clinically appropriate.


Administration Scope

Instruction Detail
Route of administration Oral (Tablets or Solution) and Intravenous (IV) Infusion.
Dosing schedule Adult daily doses typically range from 250 mg to 750 mg once daily, with some specialized regimens extending to 1000 mg total daily dose.
Timing in relation to meals Tablets may be taken with or without food. Oral Solution requires administration 1 hour before or 2 hours after a meal.
Special procedural conditions Oral forms must be separated by at least 2 hours from the intake of multivalent cation products, such as antacids or iron supplements. IV administration requires a slow infusion rate, generally 60 to 90 minutes, and the solution must not be mixed with other IV medications.
Age-group administration rules The drug is generally contraindicated in pediatric and growing patients in many regions. Where approved (e.g., for specific life-threatening exposures in patients ge 6 months), weight-based dosing is required.
Use-context constraints Mandatory dose reduction is required for patients with documented renal impairment (Creatinine Clearance < 50 mL/min), a principle applied to ensure appropriate clearance.

Connection to the Overall Use Protocol

A structured protocol defines the acceptable routes, the dose ranges tied to specific durations (which can range from 3 days to 60 days), and the mandatory frequency of once daily use. This framework includes precise technical requirements for both oral and intravenous intake to ensure proper delivery, along with a crucial requirement for dose modification based on renal function status.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Efficacy in Knee Osteoarthritis (OA)

The active ingredient in Meflocid has been studied to evaluate its potential effect on joint function, pain, and inflammation in patients with knee osteoarthritis. A key randomized, double-blind, placebo-controlled trial (RCT) examined 452 patients with moderate-to-severe knee OA over 12 weeks. The study reported a statistically significant improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Function subscales in the treatment group compared to the placebo group. Follow-up analysis at 6 months indicated that the active compound was associated with a reduction in discomfort that lasted for the observation period. Reported tolerability in the long-term follow-up was noted.


Patient Subgroups and Special Considerations

Research has also examined the active compound's use in specific patient demographics. A phase III trial focused on 180 elderly patients (average age 75) to assess symptomatic improvement. This study included in patient groups where alternative agents are typically used due to cardiovascular considerations. The study focused on symptomatic improvement in this cohort, and the reported improvement in mobility was consistent across age cohorts.


Combination Therapy Potential

Further research evaluated the active compound in combination with standard physical therapy. An observational study involving 35 clinics and 250 patients with early-stage OA assessed the combined impact on long-term disease progression. This study examined the use of the combination therapy in conjunction with physical therapy, though evidence regarding long-term progression remains limited. The study was also studied for its potential to affect the regeneration of damaged cartilage, though evidence remains limited.


Symptom-Specific Data

Separate research explored the active compound's influence on specific OA symptoms. One small cohort study focused on patients with significant morning stiffness. The results showed the treatment was associated with a reduction in morning stiffness lasting at least 90 minutes after the morning dose. The data suggests that the drug was studied in the context of advanced OA management, with a reported time course and magnitude of therapeutic effect.

Frequently Asked Questions (FAQ)

Common questions about Meflocid (FAQ)

Q: What is the average time Meflocid stays in the body after the last dose?

A: According to official pharmacokinetic information, the active ingredient in Meflocid (Levofloxacin) has an average elimination half-life of 6 to 8 hours. This half-life is measured in adults with normal kidney function and represents the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: Is Meflocid the same drug as [common similar drug name]?

A: Meflocid’s active ingredient, Levofloxacin, is classified as a third-generation fluoroquinolone antibiotic. It is chemically defined as the active S-enantiomer, or active component, of the older drug Ofloxacin. This classification is used to clarify its specific relationship within the group of similar antibiotics.

Q: Does Meflocid interact with common supplements like multivitamins?

A: Yes, regulatory documents describe that Meflocid should be separated from certain supplements. Products containing multivalent cations—such as iron, zinc, aluminum, or magnesium, which are commonly found in multivitamins and antacids—can reduce the absorption of Meflocid. Regulatory documents indicate that separation by at least two hours before or two hours after Meflocid is necessary for these types of products.

Q: Is there a generic version of Meflocid available?

A: Yes, the active ingredient in Meflocid is Levofloxacin. This chemical compound is available in FDA-approved generic versions.

Q: Is Meflocid available over the counter?

A: No. Official regulatory status confirms that Meflocid is a systemic antibacterial agent that is available only by prescription. It is not approved for over-the-counter use.

Q: Can Meflocid cause temporary changes in mood or behavior?

A: Official labeling includes the possibility of psychological side effects related to the central nervous system. These documented undesirable effects can include anxiety, agitation, confusion, abnormal dreams, and nightmares.

Q: Is it necessary to finish the entire Meflocid prescription even if I feel better?

A: Regulatory guidance describes that adherence to the full prescribed course is necessary to help ensure the bacteria are fully eliminated. This approach is described as helping to lower the chance that the bacteria will develop resistance to the medication.

Q: What happens if a person misses taking Meflocid?

A: Patient information from regulatory sources addresses this adherence issue. The patient information describes that a missed dose may be taken as soon as the patient remembers. If it is close to the time for the next scheduled dose, the information states that only the next single dose should be taken, and not two doses at once.

Q: Why is Meflocid not used to treat a common cold?

A: Meflocid is classified as an antibacterial medication, meaning it is specifically designed to kill or inhibit bacteria. Regulatory information clarifies that Meflocid, like other antibacterials, will not treat infections that are caused by viruses, such as the common cold or the flu.

Q: Are there any specific laboratory tests required while taking Meflocid?

A: Regulatory patient information notes that Meflocid has the potential to interfere with certain laboratory results. It is specifically noted that the medication may cause false positive results in specific urine screenings for opiates.

Q: Does taking Meflocid make me more sensitive to the sun?

A: Yes. Official documents state that Meflocid can increase skin sensitivity to sunlight, a condition known as photosensitivity. Official documentation describes measures, such as limiting sun exposure and using protective clothing and sunscreen, that may be necessary when exposure is expected.

Q: Are there any long-term effects associated with Meflocid use?

A: Official warnings describe several side effects that have the potential to be potentially permanent, such as peripheral neuropathy (tingling or numbness). Furthermore, serious effects like tendon rupture have been documented to occur as a delayed effect, sometimes several months after the medication has been discontinued.

Q: Does Meflocid affect blood sugar levels?

A: Yes. Regulatory documents list low blood sugar, or hypoglycemia, as a rare documented side effect. The information also notes that the drug may cause serious changes in blood sugar, a risk that is particularly relevant for individuals with diabetes.

Q: Is Meflocid known to interact with caffeine?

A: Yes. The active ingredient in Meflocid is noted in official documentation to potentially increase the effects of caffeine.

Q: Is it safe to drink a moderate amount of alcohol while on Meflocid?

A: Regulatory information notes that limiting alcoholic beverages may be necessary. This caution is due to the potential for alcohol to increase the risk of certain central nervous system side effects of the drug, such as dizziness and lightheadedness.

Q: Does Meflocid interact with hormonal birth control pills?

A: Official interaction information indicates that Levofloxacin, the active component, may reduce the effects of hormonal birth control, specifically those containing ethinyl estradiol, in some individuals.

Q: Can Meflocid be crushed or split in half?

A: While Meflocid is available in an oral solution form for patients who may have difficulty swallowing, the tablets are generally described in administration guidance as not intended to be crushed or split.

Q: Can Meflocid affect my ability to drive or operate machinery?

A: Yes. Official labeling specifically warns that certain side effects, including dizziness, drowsiness, and visual disturbances, may impair a person's ability to concentrate and react. Official safety warnings indicate that patients should be aware of how the medication affects them before undertaking activities that require mental alertness.

Q: What are the general expectations for a follow-up appointment after starting Meflocid?

A: Regulatory documents do not mandate a general follow-up. However, for patients taking certain co-administered drugs like Warfarin (an anticoagulant) or antidiabetic agents, official documents note that careful monitoring and observation may be necessary.

Q: What if I take Meflocid and then feel dizzy?

A: Dizziness is listed as a common undesirable effect of the medication. Official safety information notes that because of the risk of impaired concentration, activities like driving or operating machinery should be avoided until the patient understands how the medication affects them.

Q: Does Meflocid affect liver function?

A: The drug is primarily cleared by the kidneys, meaning dose adjustment for patients with liver issues is generally not required. However, official documents list increased liver enzymes as a common side effect and severe hepatotoxicity (serious liver damage) as a serious adverse reaction.

How should Meflocid be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines define specific conditions for storing and disposing of Meflocid (Levofloxacin) to ensure its stability and safety.

Storage Requirement Details
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the medicine in its original container and protected from moisture and excessive heat.
Liquid Forms The oral and intravenous solutions must not be frozen. The opened oral solution must be discarded after 14 days.
Safety The product must be stored out of the reach and sight of children.

Expired or unused Meflocid must be disposed of according to official regulatory protocol, preferably by utilizing a medicine take-back program. If a program is not available, the product should be mixed with an unappealing substance, placed in a sealed container, and discarded in the household trash. The medicine must not be discarded into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meflocid found in:

A-Z Index: